Most oncogene-addicted NSCLC had effective target therapies to their driver mutations including EGFR, anaplastic lymphoma kinase (ALK), ROS1, BRAF, MET, HER2, RET, K-RAS, and NTRK [38,39]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.